- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02521116
Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap (DVA-Oxymap)
To date two different instruments are commercially available to measure retinal oxygen saturation and retinal vessel diameters: Dynamic Vessel Analyzer (DVA) and Oxymap. Retinal oxygen saturation analysis is based on spectroscopic evaluation of retinal fundus images. Up to now no data comparing both instruments for the measurement of retinal oxygen saturation and vessel diameter are available in the literature.
Study objectives: To compare retinal oxygenation and retinal vessel diameters in healthy subjects and patients with diabetic retinopathy or retinal vein occlusion between 2 commercially available systems (DVA, Oxymap T1)
Study design: Open pilot study
Study population:
30 healthy volunteers, age 18-80 years 30 type 2 diabetic patients with mild or moderate non-proliferative diabetic retinopathy, age 18-80 years 30 patients with retinal vein occlusion, age 18-80 years
Topically administered medication:
Tropicamide (Mydriaticum "Agepha"®, Agepha, Vienna, Austria), dose: 1-2 drops per study day for dilation of the pupil Oxybuprocainhydrochloride combined with sodium fluorescein (Thilorbin®, Alcon Pharma GmbH, Freiburg, Germany), dose: 1 drop in one eye for measurements of intraocular pressure Nonylacidvanillylamide combined with Nicotinic-acid--ß-butoxyethylester (Finalgon®, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria): topical on the earlobe
Methods:
Dynamic vessel analyzer Oxymap T1 Blood pressure and pulse rate measurement Applanation tonometry Oxygen and carbon dioxide partial pressure measurement in arterialized blood from earlobe
Main outcome variables:
Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1
The motive for this investigation is to compare data between 2 commercially available instruments for the measurement of retinal oxygen saturation and retinal vessel diameter in healthy subjects as well as in patients with ocular disease associated with altered retinal oxygenation. Comparative data from both systems are currently not available. Data from this study will allow the comparison of studies performed with different systems. All oxygen measurement procedures are non-invasive and painless. Hence, the risk/benefit ratio appears to be acceptable.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria healthy volunteers
- normal ophthalmic findings, ametropia < 3 dpt
- men and women aged between 18 and 80 years
Exclusion Criteria:
Any of the following will exclude a subject from the study:
- participation in a clinical trial in the 3 weeks preceding the study
- symptoms of a clinically relevant illness in the 3 weeks before the first study day
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Healthy subjects
healthy study subjects, age 18-80 years
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1
Time Frame: participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days
|
participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Difference of retinal vessel diameter between DVA and Oxymap T1
Time Frame: participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days
|
participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUGEN-061014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
Sara A BelalRecruitingDiabetes (DM) | Diabetic Retinopathy (DR) | Retinopathy, Diabetic | Diabetic Retinopathy Associated With Type 2 Diabetes MellitusEgypt
-
Bojie HuCompletedProliferative Diabetic RetinopathyChina
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Centervue SpANot yet recruitingDiabetic Retinopathy (DR)
-
University of Illinois at ChicagoNational Eye Institute (NEI)RecruitingDiabetic Retinopathy (DR)United States
-
Asociación para Evitar la Ceguera en MéxicoTerminatedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoTerminatedProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Ocular Therapeutix, Inc.RecruitingNon-Proliferative Diabetic RetinopathyUnited States
-
AJU Pharm Co., Ltd.CompletedNon-Proliferative Diabetic RetinopathySouth Korea
Clinical Trials on Dynamic Vessel Analyzer
-
University Hospital, Basel, SwitzerlandUniversity of BaselRecruitingMultiple Sclerosis | Neuroinflammatory DiseasesSwitzerland
-
University Hospital, AntwerpRecruitingPreeclampsia | Endothelial Function (FMD) | Retinal VesselsBelgium
-
Medical University of ViennaRecruitingBranch Retinal Vein Occlusion | Retinal Blood Flow | Retinal Oxygen SaturationAustria
-
Medical University of ViennaCompletedType I DiabetesAustria
-
Medical University of ViennaRecruiting
-
Medical University of ViennaRecruitingReproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography in Healthy SubjectsOcular Blood FlowAustria
-
Medical University of ViennaCompletedAnterior Ischemic Optic NeuropathyAustria
-
Medical University of ViennaRecruitingAmblyopia ex Strabismus | Amblyopia ex AnisometropiaAustria
-
Medical University of ViennaRecruitingHealthy | Alzheimer Disease | Mild Cognitive ImpairmentAustria
-
Medical University of ViennaRecruitingMultiple Sclerosis, Relapsing-Remitting | Optic NeuritisAustria